Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 17, 2026Cancer Immunology ImmunotherapyOpen Access

Identification of mITGB2 as an MHC-II neoantigen using hepatocellular carcinoma organoids

View Full Paper
Ask AI
Bookmark
Share

Authors

DZDeyuan ZhongYCYahui ChenYRYuan Ren

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Zhong et al. (2026) studied this question.

synapsesocial.com/papers/6aabb73d5f706d05830e630bhttps://doi.org/10.1007/s00262-026-04542-5
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1HMGB2 drives tumor progression and shapes the immunosuppressive microenvironment in hepatocellular carcinoma: insights from multi-omics analysis2024 · 13 citations
  2. 2Abstract 1204: Neoantigen MHC presentability ratios influence the tumor microenvironment and response to immunotherapy2024 · 1 citations
  3. 3Identification of a new HLA-A*0201-restricted cytotoxic T lymphocyte epitope from TC2N2024
  4. 4MHC-II-restricted neoantigen expression drives tumor infiltration, activation, and maintenance of nonspecific T cells in lung cancer 22511692026
  5. 5Identification of Tumor Antigens and Immune Subtypes in Hepatocellular Carcinoma From a Multiomics Perspective2025